^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CG expression

    i
    Other names: PIK3CG, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma, Phosphatidylinositol 4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma Isoform, Serine/Threonine Protein Kinase PIK3CG, PtdIns-3-Kinase Subunit P110-Gamma, PtdIns-3-Kinase Subunit Gamma, PI3-Kinase Subunit Gamma, PI3Kgamma, P110gamma, P120-PI3K, Phosphatidylinositol-4 5-Bisphosphate 3-Kinase 110 KDa Catalytic Subunit Gamma, Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Gamma Isoform, Phosphatidylin
    Entrez ID:
    5294
    Related biomarkers:
    Expression
    Mutation
    8d
    Overexpression of PIK3CG in Cancer Cells Promotes Lung Cancer Cell Migration and Metastasis Through Enhanced MMPs Expression and Neutrophil Recruitment and Activation. (PubMed, Biochem Genet)
    Two PIK3CG-specific inhibitors, Eganelisib and CAY10505, were used to treat A549 and H1299 cells...Co-culture with neutrophils, soluble extracts of neutrophils and cathepsin G all promoted the migration of lung cancer cells. PIK3CG overexpression in tumor cells significantly promoted the migration and metastasis of lung cancer cell.
    Journal
    |
    PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • CTSG (Cathepsin G)
    |
    PIK3CG expression • PIK3CG overexpression
    |
    eganelisib (IPI-549)
    3ms
    Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway. (PubMed, Pharmaceuticals (Basel))
    In addition, ISL significantly down-regulated the protein expression of PIK3CG, AKT, p-AKT, p-GSK3β, CDK1, NF-κB and Bcl-2; up-regulated ESR2 and Bax; decreased the ratio of p-AKT/AKT and p-GSK3β/GSK3β; and increased the Bax/Bcl-2 ratio. This study indicates that ISL can inhibit the growth of CRC cells and induce apoptosis, which may be related to the up-regulation of ESR2 and inhibition of the PI3K/Akt signalling pathway.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • BAX (BCL2-associated X protein) • CDK1 (Cyclin-dependent kinase 1)
    |
    PIK3CG expression
    10ms
    In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts. (PubMed, Pediatr Blood Cancer)
    Duvelisib demonstrated limited in vivo activity against ALL PDXs.
    Preclinical • Journal
    |
    PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • IL2RG (Interleukin 2 Receptor Subunit Gamma)
    |
    PIK3CG expression
    |
    Copiktra (duvelisib)
    2years
    Repressing phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma by microRNA-142-3p restrains the progression of hepatocellular carcinoma. (PubMed, Bioengineered)
    PIK3CG overexpression dampened the anti-tumor effect of miR-142-3p. miR-142-3p repressed HCC invasion and intensified apoptosis to restrain HCC by abating the PIK3CG-mediated PI3K/AKT/HIF-1α pathway.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • MIR142 (MicroRNA 142)
    |
    PIK3CG expression • PIK3CG overexpression • miR-142 overexpression
    over2years
    Evaluation of pathway specific inhibitors MK-2206, Buparlisib, Silmitasertib and Dinaciclib in ten pancreatic cancer cell lines (DGHO 2021)
    The present study revealed distinct antitumor effects of 4 specific pathway inhibitors against PDAC cell lines. In comparison to PIK3CG wild type cell lines we observed no significant different response to Buparlisib in Capan-1 cells, which carry a PIK3CGc.2480C> G mutation. PDAC cell lines with common KRAS point mutations and specific TP53 mutations reacted less sensitive to MK-2206 and Silmitasertib.
    Preclinical
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • AKT3 (V-akt murine thymoma viral oncogene homolog 3) • CDK1 (Cyclin-dependent kinase 1)
    |
    TP53 mutation • KRAS mutation • PIK3CA mutation • PIK3CG expression • TP53 expression
    |
    MK-2206 • buparlisib (AN2025) • dinaciclib (MK-7965) • silmitasertib (CX-4945)
    almost3years
    The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers. (PubMed, Front Oncol)
    NR0B2 is a prognosis factor for patient survival in liver cancers. MAPK and PI3K oppositely modulate NR0B2 expression, and NR0B2 gene upregulation might serve as a therapeutic responsiveness factor in anti-PI3K therapy for liver cancer.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
    |
    PIK3CG expression • PIK3CA expression
    over3years
    Pik3cg is a potential therapeutic target in androgen receptor-indifferent metastatic prostate cancer. (PubMed, Am J Pathol)
    Immunohistochemistry in human prostate cancer specimens found that expression of PIK3CG is significantly associated with advanced clinical stages. Taken together, these results suggest that Pik3cg plays an important role in the progression and metastasis of prostate cancer, and may represent a new therapeutic target in the metastatic castration-resistant prostate cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • AR (Androgen receptor) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
    |
    AR expression • PIK3CG expression
    over3years
    [VIRTUAL] Evaluation of the PI3K / AKT and CDK pathway inhibitors MK-2206, buparlisib, silmitasertib and dinaciclib in eleven pancreatic cancer cell lines (DGHO 2020)
    The present study revealed distinct antitumor effects against PC cell lines by PI3K/AKT or CDK pathway intervention. Sequencing data revealed genetic background changes in PC cell lines. These results provide data necessary for studies in exploring relationship between altered genetic background and inhibitor Response.
    Preclinical
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
    |
    PIK3CA mutation • PIK3CG expression
    |
    MK-2206 • buparlisib (AN2025) • dinaciclib (MK-7965) • silmitasertib (CX-4945)
    over3years
    [VIRTUAL] Evaluation of the PI3K / AKT and CDK pathway inhibitors MK-2206, buparlisib, silmitasertib and dinaciclib in eleven pancreatic cancer cell lines (DGHO 2020)
    The present study revealed distinct antitumor effects against PC cell lines by PI3K/AKT or CDK pathway intervention. Sequencing data revealed genetic background changes in PC cell lines. These results provide data necessary for studies in exploring relationship between altered genetic background and inhibitor Response.
    Preclinical
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
    |
    PIK3CA mutation • PIK3CG expression
    |
    MK-2206 • buparlisib (AN2025) • dinaciclib (MK-7965) • silmitasertib (CX-4945)
    over3years
    [VIRTUAL] Evaluation of the PI3K / AKT and CDK pathway inhibitors MK-2206, buparlisib, silmitasertib and dinaciclib in eleven pancreatic cancer cell lines (DGHO 2020)
    The present study revealed distinct antitumor effects against PC cell lines by PI3K/AKT or CDK pathway intervention. Sequencing data revealed genetic background changes in PC cell lines. These results provide data necessary for studies in exploring relationship between altered genetic background and inhibitor Response.
    Preclinical
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
    |
    PIK3CA mutation • PIK3CG expression
    |
    MK-2206 • buparlisib (AN2025) • dinaciclib (MK-7965) • silmitasertib (CX-4945)
    almost4years
    [VIRTUAL] Single cell expression analysis of PIK3 genes to direct solid tumor treatment with the dual PI3K-δ,γ inhibitor duvelisib (AACR-II 2020)
    These results indicate that PI3Kδ expression is observed in both the immune cells which are fashioning the suppressive microenvironment and in cancer cells. These findings suggest an approach to identify patients for treatment guided by cell type expression of PI3K isoforms, and provide strategies for duvelisib use as monotherapy and in combinations with PD-1 checkpoint inhibitors and other agents.
    BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CD8 (cluster of differentiation 8) • BRCA (Breast cancer early onset) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
    |
    PIK3CD expression • PIK3CG expression
    |
    Copiktra (duvelisib)